Table 2 The specificity of the Biomeme and Precision Biomonitoring SARS-CoV-2 tests.

From: Evaluation of mobile real-time polymerase chain reaction tests for the detection of severe acute respiratory syndrome coronavirus 2

Confirmed pathogen

Biomeme SARS-CoV-2 test

Precision Biomonitoring TripleLock SARS-CoV-2 test

Orf1ab gene

S gene

RNA process control

5′UTR gene

E gene

RNaseP (averaged)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

12.60

12.78

No Ct*

14.27

11.17

41.12

Severe acute respiratory syndrome coronavirus (SARS-CoV-1)

No Ct

No Ct

26.15

16.38

13.26

29.20

Middle east respiratory syndrome (MERS) virus

No Ct

No Ct

26.44

No Ct

No Ct

30.95

Infectious bronchitis virus (IBV) Iowa

No Ct

No Ct

31.44

Pandemic H1N1 (pH1N1) virus

No Ct

No Ct

29.76

Porcine epidemic diarrhea virus (PEDV) Colorado

No Ct

No Ct

31.98

Transmissible gastroenteritis (TGE) virus F-216

No Ct

No Ct

31.21

Influenza A H3N2

No Ct

No Ct

25.87

No Ct

No Ct

26.29

Influenza A H1N1

No Ct

No Ct

27.11

No Ct

No Ct

28.41

Rhinovirus (ENR/RHV)

No Ct

No Ct

13.34**

No Ct

No Ct

30.40

Human coronavirus OC43 (HCoV-OC43)

No Ct

No Ct

26.56

No Ct

No Ct

27.65

Human coronavirus 229E (HCoV-229E)

No Ct

No Ct

27.62

No Ct

No Ct

23.91

Human coronavirus NL63 (HCoV-NL63)

No Ct

No Ct

26.79

No Ct

No Ct

27.57

Human coronavirus HKU1 (HCoV-HKU1)

No Ct

No Ct

25.24

No Ct

No Ct

27.07

Human metapneumovirus (hMPV)

No Ct

No Ct

25.59

No Ct

No Ct

29.73

Parainfluenza virus 1 (PIV-1)

No Ct

No Ct

12.25**

No Ct

No Ct

26.77

Parainfluenza virus 2 (PIV-2)

No Ct

No Ct

12.94**

No Ct

No Ct

26.99

Parainfluenza virus 3 (PIV-3)

No Ct

No Ct

11.23**

No Ct

No Ct

27.50

Parainfluenza virus 4 (PIV-4)

No Ct

No Ct

12.61**

No Ct

No Ct

29.64

Respiratory syncytial virus A (RSV-A)

No Ct

No Ct

13.53**

No Ct

No Ct

26.79

Respiratory syncytial virus B (RSV-B)

No Ct

No Ct

13.96**

Adenovirus

No Ct

No Ct

26.32

No Ct

No Ct

28.47

Influenza B

No Ct

No Ct

13.53**

No Ct

No Ct

29.76

Bocavirus

No Ct

No Ct

26.77

Haemophilus influenzae

No Ct***

No Ct

27.51

Streptococcus pneumoniae

No Ct

No Ct

27.65

Streptococcus pyogenes

No Ct

No Ct

27.94

Candida albicans

No Ct

No Ct

27.51

Pseudomonas aeruginosa

No Ct***

No Ct

27.57

Staphylococcus epidermis

No Ct

No Ct

27.59

Staphylococcus salivarius

No Ct***

No Ct

27.46

Mycoplasma pneumoniae

No Ct

No Ct

27.21

Chlamydia pneumoniae

No Ct

No Ct

27.18

Legionella pneumophila

No Ct

No Ct

24.27

Bordetella pertussis

No Ct

No Ct

No Ct

No Ct

No Ct

Bordetella parapertussis

No Ct

No Ct

No Ct

No Ct

35.17

Pneumocystis jirovecii

No Ct

No Ct

No Ct

No Ct

No Ct

  1. The RNA from seven different cell culture-amplified coronaviruses was used to set up the Biomeme SARS-CoV-2 assay on Biomeme Franklin three9 in order to assess the specificity of the test to SARS-CoV-2. Mid-turbinate swabs from common respiratory pathogens were also used to test for cross-reactivity with both the Biomeme and Precision Biomonitoring SARS-CoV-2 tests. Common bacteria were also tested with the Precision Biomonitoring assay, not the Biomeme test.
  2. *According to the Biomeme SARS-CoV-2 test design, the RNA Process Control may not amplify (No Ct) when the two SARS-CoV-2 gene signals are very strong.
  3. **RNA used was previously extracted for use on xTAG RVP FAST v2 (Luminex, Toronto, Canada) or ResPlex II (Qiagen, Hilden, Germany), which both use MS2 as an internal control, hence much lower Ct values.
  4. ***Threshold of 500 RFU was not met, Ct value adjusted.